Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06164795
Recruiting Observational

Sequential Therapies After Osteoanabolic Treatment

NCT06164795 · tracked via the Priya Life Science Italy tracker
Sponsor
424 General Military Hospital
Phase
Observational
Started
2023-11-25
Last updated
2026-07-22

Condition(s) studied

Osteoporosis, Postmenopausal

Investigational drug(s) / intervention(s)

Zoledronate →Denosumab →Teriparatide →Romosozumab →Abaloparatide Injection (80 mcg)

Zoledronate: intravenous infusion

Denosumab: subcutaneous injection

Teriparatide: subcutaneous injection

Romosozumab: subcutaneous injection

Abaloparatide Injection (80 mcg): daily subcutaneous injection

Study summary

12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics

Eligibility

Sex
FEMALE
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: • Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide Exclusion Criteria: * a bone disease other than postmenopausal osteoporosis * use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study * creatinine clearance \<60 mL/min/1.73 m2 * liver failure * any type of cancer * uncontrolled endocrine diseases * serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L) * hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients

Primary outcome measure(s)

  • lumbar spine bone mineral density — baseline to 12 months
    bone mineral density changes at the lumbar spine at 12 months measured by dual-energy absorptiometry (DXA)

Trial sites (8)

FacilityCityRegionStatus
251 Airforce & VA General Hospital Athens Greece Recruiting
First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens Athens Greece Recruiting
, KAT General Hospital Athens Greece Recruiting
424 General Military Hospital Thessaloniki Greece Recruiting
Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan Italy Recruiting
Campus Bio-Medico University Roma Italy Recruiting
Department of Medicine, Surgery and Neurosciences, University of Siena Siena Italy Recruiting
University-Hospital S. Maria della Misericordia Udine Italy Recruiting

More 424 General Military Hospital trials in Italy

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) Active, not recruiting

Other trials for the same condition

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06164795 on ClinicalTrials.gov ↗ ← All trials in Italy